OFT alleges that GSK breached competition law to delay rivals' generic copies of Seroxat

The OFT alleges that GSK breached competition law to delay rivals' generic copies of Seroxat, one of its most profitable drugs. See BBC News report. "GlaxoSmithKline (GSK) has been accused of market "abuse" by the consumer watchdog, the Office of Fair Trading (OFT). The OFT alleges that the pharmaceutical giant paid rivals to delay the release their own versions of GSK's Seroxat treatment. Alpharma, Generics UK and Norton Healthcare all received money not to enter the market with their copies of Seroxat, it said."

 

We must not be surprised at GlaxoSmithKline being accused of nefarious activities. You can read here of several more breaches of the Law by GSK with regard to the antidepressant, Seroxat, and other pharmaceutical junk that GSK manufactures. Some further examples of its criminality can be found on this page.